Form 4: Syros Pharmaceuticals' Chief Medical Officer Sells Shares
SEC Form 4 Filing
David Roth, Chief Medical Officer of Syros Pharmaceuticals, sold 10,451 shares of common stock on April 3, 2024, at a price of $4.95 per share.
Summary
- On April 3, 2024, David Roth, the Chief Medical Officer of Syros Pharmaceuticals, sold 10,451 shares of the company's common stock.
- The sale was executed at a price of $4.95 per share.
- Following the transaction, Roth directly owns 0 shares of Syros Pharmaceuticals.
- The sale was conducted under a pre-arranged trading plan adopted on March 27, 2023, in accordance with Rule 10b5-1.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. The use of a 10b5-1 plan suggests the sale was pre-planned. Therefore, the sentiment is neutral.
Industry Context
Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| March 27, 2023 | Date of adoption of the Rule 10b5-1 trading plan. |
| April 03, 2024 | Date of the stock sale transaction. |
| April 05, 2024 | Date of signature on the Form 4 filing. |
Keywords
Syros Pharmaceuticals, SYRS, David Roth, Chief Medical Officer, Stock Sale, Form 4, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.